GALM

Across TCGA pan-cancer cohorts, GALM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALM data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GALM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GALM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where GALM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.389	.005	47	view →
PDAC	DFS	Median	All	0.517	0.301	<.001	42	view →
UCEC	OS	Tertile	All	0.886	1.000	.016	8	view →
LUAD	OS	Quartile	II,III,IV	0.735	0.287	.004	6	view →
LSCC	OS	Tertile	II,III,IV	0.569	0.903	.009	4	view →
GBM	DFS	Median	All	0.427	0.310	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALM–CCRCC (DFS)

Open the CCRCC breakdown →